NasdaqCM:NAGEPersonal Products
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy?
In early May 2026, Niagen Bioscience, Inc. launched its Niagen Plus clinician-directed telehealth platform in the U.S., offering prescription-only, pharmaceutical-grade Niagen via a first-of-its-kind at-home subcutaneous injection kit dispensed through licensed 503A pharmacies.
This move marks Niagen Bioscience's first direct-to-client access model, potentially widening its addressable market by combining telehealth, at-home delivery, and injectable NAD+ support under medical...